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This study confirms that renal artery stenting can be
performed with a nearly negligible periprocedure compli-
cation rate, and 100% assisted patency can be obtained. In
patients undergoing intervention for hypertension, the
benefit is only transient, but renal function significantly
improves with renal artery stenting.
The etiology of renal disease is multifactorial, involving
systemic lipid disorders, increasing age, segmental glomer-
ulosclerosis, fibrosis, hypertensive nephropathy, endothe-
lial dysfunction, and diabetic nephropathy. Renovascular
disease is just one factor that when reversed with renal
artery stenting has the potential to delay progressive loss of
renal function over time. The ability to arrest this progres-
sion has not been established. Further randomized con-
trolled trials will be needed to determine the impact on
hemodialysis, cardiac events, and mortality.
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Dr R. Eugene Zierler (Seattle, Wash). This report from the
Madigan Army Medical Center adds to the growing body of
evidence that documents the results of percutaneous interventions
for atherosclerotic renal artery disease. Despite lingering concerns
over the efficacy and durability of renal artery stenting, the favor-
able early technical results of catheter-based interventions, and the
relatively high risks of open surgery in the atherosclerotic patient
population, have made the less-invasive approach overwhelmingly
preferred. In fact, renal artery bypass surgery in this setting has all29 renal artery stents in 18 patients, I suspect that the correspond-
ing number of open renal artery operations was even lower. Look-
ing at outcomes in terms of hypertension and renal function, the
main conclusion is that improvement in blood pressure control was
transient; however, the rate of decline in renal function was signif-
icantly better than in a similar cohort of patients followed without
intervention.
Since the indications for intervention in this study are listed as
drug-resistant hypertension in 77% and renal salvage in 23%, this
suggests that only a minority of the patients (that is, 23% or about
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and timing are the key factors in maximizing benefit and minimiz-
ing both the risk and cost of intervention. The results of this study
focus our attention on the level of renal function and rate of renal
function decline. Other clinical features that may correlate with
outcome include kidney length (renal atrophy), severity of renal
artery stenosis, unilateral or bilateral renal artery disease, and renal
resistive index or other measures of parenchymal blood flow. With
that in mind, I have the following questions:
Number one, experience suggests that there is a “window of
opportunity” for renal revascularization in preservation of renal
function. Other than rate of decline in renal function, what factors
would you take into account when selecting patients with renal
insufficiency for renal artery intervention?
Number two, some hypertensive patients do appear to benefit
from renal revascularization, although this was not shown in your
study. Why do you think this patient group failed to respond to
intervention? Are there any situations in which you would still
recommend renal artery intervention for hypertension alone?
Number three, the manuscript mentions that nine of the
patients followed without intervention underwent renal MRA, and
a renal artery stenosis of 60% was not confirmed in five. Was the
initial diagnosis of renal artery stenosis in these patients made by
duplex ultrasound? If this is the case, can the authors comment on
this apparent discrepancy between these two imaging methods?
I appreciate the opportunity to review and discuss this paper.
Dr Zachary Arthurs. Thank you, Dr Zierler. The first ques-
tion is a question we are working through right now. Who are the
patients that are responders and who should we treat? The rate of
decline and the window of opportunity is something that we are
now looking for and hopefully we can randomize these patients
based on the indication for renal salvage. The point at which to
intervene we do not know.
The factors that we look for that are appealing are the fact that we
have now realized that the kidney obviously has humoral function.
The impact of the renal angiotensin has well been defined with split
renal function and its potential to damage a kidney with unilateral
renal artery stenosis. The endothelium also has endocrine function
impacting blood pressure control, and now the natriuretic peptides
released from the heart are recognized as having an endocrine role. All
these factors may play a role in renal artery hypertension. Maybe
measuring natriuretic peptide could give the clinician a marker along
with LVH that the patient’s heart is attempting to respond to volume
overload caused by a renal artery lesion. This is one of the measures
that we would like to explore. We have not yet defined the percentage
of renal function decline that should be treated with renal artery
stenting. I think it is an excellent point.
The concept of why did the hypertensive patients fail. I think
that is what was most intriguing to me. Many of these patients are
not taking any antihypertensive medications after their procedure,
but progressively the medications are returned as their hyperten-
sion returns. This suggests that maybe there is another humoral or
neural mechanism that allows an initial response but over time the
kidney fails once again. The kidney may lose its auto feedback
mechanisms, or it may be progression of underlying parenchymal
disease. I do not have a real good answer to explain that initial
transient response.
At this point I should recognize the fact that Dr Zierler,
having dedicated so much time to the vascular laboratory, would
have picked out the four discordances in MRA versus duplex and I
did not look at those specifically. If there was a patient that was felt
to maybe be poorly compliant, maybe could have gone up on their
medications and the lesion was borderline on ultrasound, those
were the patients that we would get a confirmatory study. If the
MRA was either borderline or less than our ultrasound, we would
use that to watch that patient and attempt medication control.
Dr James Watson (Seattle, Wash). You just answered one of
my questions but I am curious as to what are the current indica-
tions for renal artery intervention at Madigan, and who will you
intervene on when you see this patient in clinic?Dr Arthurs. We are becoming extremely cautionary for inter-
vening for hypertension as a sole indication and we are looking at
evaluating a series of patients who are randomized based on their
rate of renal function decline.
DrFredWeaver (Los Angeles, Calif). I may have missed it but
did you provide any numbers with regard to immediate technical
success of your stenting procedures?
DrArthurs. I left that out completely because there was 100%
technical success at the time of the procedure and we had no
periprocedural morbidity associated with regards to acute throm-
bosis, embolization, dissection or groin complications in this small
series.
Dr Weaver. Do you have any follow-up data with regards to
restenosis?
Dr Arthurs. At the 3 and 6-month mark, we have docu-
mented imaging for restenosis, and I do have a restenosis slide in
the manuscript, but it is roughly the same across the cohort of 78%
with 100% secondary patency.
Dr Weaver. The observation that the hypertensive improve-
ment deteriorates after a year has been made by a number of
authors, as you know. The University of Rochester reported a large
series where at 5 years, the hypertension benefit deteriorated over
the 5-year followup despite the fact that 100% of the renal artery
stents were patent. With regards to renal function, do you use any
renal protection when you do these procedures, either embolic
protection or CO2, to minimize renal damage? As you know, with
renal stenting, renal function actually deteriorates in a significant
number of patients. Either the iodinated contrast and/or choles-
terol embolization from the plaque is hypothesized as the culprit.
What are your thoughts on renal protection?
Dr Arthurs. Periprocedural data were limited, but no protec-
tion devices were used. There were cases that required adjunctive
measures such as lytic therapy.
Dr Wesley Moore (Los Angeles, Calif). As Dr Zierler indi-
cated in his discussion, with the availability of stent balloon angio-
plasty, there was a rapid transition from direct surgical repair to this
technique with the assumption that the two were equivalent. I
think that we ought to take a hard look at whether or not they
really are equivalent. I wonder if you had the opportunity to
compare the data that you have presented with earlier surgical
experience. My recollection is that the cure or improved rate using
the same parameters that you have described as about 75% over
long periods of time when direct surgical reconstruction of the
renal artery was carried out. In view of your results and the results
reported from UCSD this morning, I wonder if we ought to
reconsider whether or not the two are equivalent and consider at
the risk of being considered a surgical dinosaur maybe we ought to
start looking again at direct renal surgical repair.
Dr Arthurs. Sir, I agree completely. It is hard for me to see
how we transitioned to where we have. There is only one paper that
I know of that has a comparison of medical management to
operative revascularization, and that was in 1973. A large propor-
tion of patients had fibromuscular dysplasia, only about 40 patients
in each group, and they were able to show a benefit with regard to
blood pressure and creatinine. They also had extremely long
follow-up, 10 years. It suggested that there was a survival benefit as
compared to medical management. What you sacrifice is a periop-
erative mortality rate associated with surgery, but that is the only
study I know that is medical management compared to surgery.
Then we made the leap to angioplasty. To echo Dr Schneider’s
words at this conference, once you go to endoluminal therapy, the
endoluminal problems are fixed with another endoluminal ther-
apy. Once angioplasty was known to have a high restenosis rate, an
acute thrombosis rate, and a learning curve, instead of going back
to surgery we went on to stents. Now, we utilize primary stents
primarily in the renal artery. The comparisons of angioplasty to
surgery are really marginal and then we do not have any studies
with renal artery stenting versus medical management or stenting
versus surgery for that matter. It would take a well-designed
randomized controlled trial to define these differences in outcome.
